Zobrazeno 1 - 10 of 13 pro vyhledávání: '"Jenneke J. Kloezeman"'
1
Akademický článek
The Sequence of Delta24-RGD and TMZ Administration in Malignant Glioma Affects the Role of CD8+T Cell Anti-tumor Activity
Autor: Anne Kleijn, Wouter van den Bossche, Erik S. Haefner, Zineb Belcaid, Chantal Burghoorn-Maas, Jenneke J. Kloezeman, Suzan D. Pas, Sieger Leenstra, Reno Debets, Jeroen de Vrij, Clemens M.F. Dirven, Martine L.M. Lamfers
Publikováno v: Molecular Therapy: Oncolytics, Vol 5, Iss C, Pp 11-19 (2017)
The conditionally replicating oncolytic adenovirus Delta24-RGD (Ad) is currently under investigation in clinical trials for glioblastoma, including in combination with temozolomide (TMZ), the standard chemotherapy for this tumor. Previously, we showe
Externí odkaz: https://doaj.org/article/638eb206e27f41b2bcb5dca670a9a6cd
Zobrazit plný text záznamu
5
Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM:A Phase I Clinical Trial Including Correlative Studies
Autor: Erik H.P. van Putten, Anne Kleijn, Victor W. van Beusechem, David Noske, Cor H.J. Lamers, Anna L. de Goede, Sander Idema, Daphna Hoefnagel, Jenneke J. Kloezeman, Juan Fueyo, Frederick F. Lang, Charlotte E. Teunissen, René M. Vernhout, Cathy Bakker, Winald Gerritsen, David T. Curiel, Arnold Vulto, Martine L.M. Lamfers, Clemens M.F. Dirven
Publikováno v: van Putten, E H P, Kleijn, A, van Beusechem, V W, Noske, D, Lamers, C H J, de Goede, A L, Idema, S, Hoefnagel, D, Kloezeman, J J, Fueyo, J, Lang, F F, Teunissen, C E, Vernhout, R M, Bakker, C, Gerritsen, W, Curiel, D T, Vulto, A, Lamfers, M L M & Dirven, C M F 2022, ' Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM : A Phase I Clinical Trial Including Correlative Studies ', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 28, no. 8, pp. 1572-1585 . https://doi.org/10.1158/1078-0432.CCR-21-3324
Clinical Cancer Research, 28, 8, pp. 1572-1585
Clinical Cancer Research, 28, 1572-1585
Clinical Cancer Research, 28(8), 1572-1585. American Association for Cancer Research Inc.
Clinical cancer research : an official journal of the American Association for Cancer Research, 28(8), 1572-1585. American Association for Cancer Research Inc.
Purpose: Testing safety of Delta24-RGD (DNX-2401), an oncolytic adenovirus, locally delivered by convection enhanced delivery (CED) in tumor and surrounding brain of patients with recurrent glioblastoma. Patients and Methods: Dose-escalation phase I
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e98a4f8e026196acc27eb52c8fe11327
https://research.vumc.nl/en/publications/c446737f-705c-42cd-b2f7-497eb4aee279
Zobrazit plný text záznamu
6
Akademický článek
The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells.
Autor: Lotte M E Berghauser Pont, Anne Kleijn, Jenneke J Kloezeman, Wouter van den Bossche, Johanna K Kaufmann, Jeroen de Vrij, Sieger Leenstra, Clemens M F Dirven, Martine L M Lamfers
Publikováno v: PLoS ONE, Vol 10, Iss 5, p e0127058 (2015)
A phase I/II trial for glioblastoma with the oncolytic adenovirus Delta24-RGD was recently completed. Delta24-RGD conditionally replicates in cells with a disrupted retinoblastoma-pathway and enters cells via αvβ3/5 integrins. Glioblastomas are dif
Externí odkaz: https://doaj.org/article/23702382f25b4061a5448aa9022693d4
Zobrazit plný text záznamu
7
The Sequence of Delta24-RGD and TMZ Administration in Malignant Glioma Affects the Role of CD8
Autor: Anne, Kleijn, Wouter, van den Bossche, Erik S, Haefner, Zineb, Belcaid, Chantal, Burghoorn-Maas, Jenneke J, Kloezeman, Suzan D, Pas, Sieger, Leenstra, Reno, Debets, Jeroen, de Vrij, Clemens M F, Dirven, Martine L M, Lamfers
Publikováno v: Molecular Therapy Oncolytics
The conditionally replicating oncolytic adenovirus Delta24-RGD (Ad) is currently under investigation in clinical trials for glioblastoma, including in combination with temozolomide (TMZ), the standard chemotherapy for this tumor. Previously, we showe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ec58efea241ccd1b1c59a7bf9a83216d
https://pubmed.ncbi.nlm.nih.gov/28480325
Zobrazit plný text záznamu
8
Therapeutic concentrations of anti-epileptic drugs do not inhibit the activity of the oncolytic adenovirus Delta24-RGD in malignant glioma
Autor: Jonas, de Jonge, Lotte M E, Berghauser Pont, Sander, Idema, Jenneke J, Kloezeman, David, Noske, Clemens M F, Dirven, Martine L M, Lamfers
Publikováno v: The journal of gene medicine. 15(3-4)
The oncolytic adenovirus Delta24-RGD is currently being tested in phase I trials for the treatment of glioblastoma (GBM). Literature suggests that frequently prescribed anticonvulsants for these patients, phenytoin (PHE), valproic acid (VPA) and leve
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::97b2516069e3488912ed2451556cbc3d
https://pubmed.ncbi.nlm.nih.gov/23606319
Zobrazit plný text záznamu
9
Akademický článek
Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy.
Autor: Belcaid Z; Department of Neurosurgery, Brain Tumor Center, Erasmus University Medical Center, Rotterdam, The Netherlands.; Laboratory of Tumor Immunology, Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Berrevoets C; Laboratory of Tumor Immunology, Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Choi J; Department of Neurosurgery, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., van Beelen E; Department of Neurosurgery, Brain Tumor Center, Erasmus University Medical Center, Rotterdam, The Netherlands., Stavrakaki E; Department of Neurosurgery, Brain Tumor Center, Erasmus University Medical Center, Rotterdam, The Netherlands., Pierson T; Department of Neurosurgery, Brain Tumor Center, Erasmus University Medical Center, Rotterdam, The Netherlands., Kloezeman J; Department of Neurosurgery, Brain Tumor Center, Erasmus University Medical Center, Rotterdam, The Netherlands., Routkevitch D; Department of Neurosurgery, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., van der Kaaij M; Department of Neurosurgery, Brain Tumor Center, Erasmus University Medical Center, Rotterdam, The Netherlands., van der Ploeg A; Department of Neurosurgery, Brain Tumor Center, Erasmus University Medical Center, Rotterdam, The Netherlands., Mathios D; Department of Neurosurgery, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Sleijfer S; Laboratory of Tumor Immunology, Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Dirven C; Department of Neurosurgery, Brain Tumor Center, Erasmus University Medical Center, Rotterdam, The Netherlands., Lim M; Department of Neurosurgery, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Debets R; Laboratory of Tumor Immunology, Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Lamfers MLM; Department of Neurosurgery, Brain Tumor Center, Erasmus University Medical Center, Rotterdam, The Netherlands.
Publikováno v: Neuro-oncology advances [Neurooncol Adv] 2020 Feb 03; Vol. 2 (1), pp. vdaa011. Date of Electronic Publication: 2020 Feb 03 (Print Publication: 2020).
Zobrazit plný text záznamu
10
Akademický článek
TP53 mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in TP53 wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2.
Autor: Venkatesan S; Department of Neurosurgery, Brain Tumor Center Erasmus MC, Rotterdam, The Netherlands., Hoogstraat M; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.; Center for Personalized Cancer Treatment (CPCT), University Medical Center Utrecht, Utrecht, The Netherlands., Caljouw E; Pepscope BV, Utrecht, The Netherlands., Pierson T; Department of Neurosurgery, Brain Tumor Center Erasmus MC, Rotterdam, The Netherlands., Spoor JK; Department of Neurosurgery, Brain Tumor Center Erasmus MC, Rotterdam, The Netherlands., Zeneyedpour L; Department of Neurology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Dubbink HJ; Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Dekker LJ; Department of Neurology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., van der Kaaij M; Department of Neurosurgery, Brain Tumor Center Erasmus MC, Rotterdam, The Netherlands., Kloezeman J; Department of Neurosurgery, Brain Tumor Center Erasmus MC, Rotterdam, The Netherlands., Berghauser Pont LM; Department of Neurosurgery, Brain Tumor Center Erasmus MC, Rotterdam, The Netherlands., Besselink NJ; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.; Center for Personalized Cancer Treatment (CPCT), University Medical Center Utrecht, Utrecht, The Netherlands.; Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands., Luider TM; Department of Neurology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Joore J; Pepscope BV, Utrecht, The Netherlands., Martens JW; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.; Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Lamfers ML; Department of Neurosurgery, Brain Tumor Center Erasmus MC, Rotterdam, The Netherlands., Sleijfer S; Center for Personalized Cancer Treatment (CPCT), University Medical Center Utrecht, Utrecht, The Netherlands.; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.; Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Leenstra S; Department of Neurosurgery, Brain Tumor Center Erasmus MC, Rotterdam, The Netherlands.; Department of Neurosurgery, St. Elisabeth Hospital Tilburg, Tilburg, The Netherlands.
Publikováno v: Oncotarget [Oncotarget] 2016 Sep 06; Vol. 7 (36), pp. 58435-58444.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje